Press Release Oncology Venture is issuing 751,879 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

    NEXT STORY
    Multiverse Investment Fund Announces Portfolio Company’s Participation in Coronavirus Vaccine Development
    PREV STORY
    Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (letermovir) From AiCuris Anti-Infective Cures GmbH
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TiGenix presenteert positieve week 52-resultaten van Cx601 op het World Congress of Gastroenterology tijdens de ACG 2017 vergadering

    PERSBERICHT TiGenix presenteert  positieve week 52-resultaten van Cx601 op het World Congress of Gastroenterology ...

    author_avatar
    NASDAQ Market News

    Beyond Celiac partners with imaware™ to expand use of at-home celiac disease testing for faster medical diagnosis

    Innovative approach to celiac disease testing could improve the incredibly low diagnosis rate of ...

    author_avatar
    NASDAQ Market News

    CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

    ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR ...

    author_avatar
    NASDAQ Market News